NCT06681389View on ClinicalTrials.gov

A Study of NP-201 Acetate Injection in Healthy Adult Volunteers and in Patients With Mild-To-Moderate Active Ulcerative Colitis

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 25, 2024

Primary Completion Date

March 25, 2025

Study Completion Date

May 5, 2025

Conditions

Healthy Adult VolunteersActive Ulcerative ColitisActive Ulcerative Colitis (UC)

Interventions

DRUG

NP-201 acetate injection (Part A)

Route of administration- Sub cutaneous. Dosage interval and frequency: MAD1-200mg daily for 5 days; MAD2- 300mg daily for 5 days, MAD3- 400mg daily for 5 days

DRUG

Placebo

Matching placebo administered across Part A and Part B

Trial Locations (1)

5000

RECRUITING

CMAX Clinical Research Pty Ltd, Adelaide

All Listed Sponsors

lead

NIBEC Co., Ltd.

INDUSTRY